Eton Pharmaceuticals completes acquisition of Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. to advance treatment for Wilson Disease

Eton Pharmaceuticals, Inc. has successfully acquired Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. This strategic acquisition demonstrates Eton Pharmaceuticals' commitment to advancing treatment options for rare diseases, particularly in the case of Wilson Disease. Eton Pharmaceuticals plans to leverage its metabolic sales force to support healthcare professionals dedicated to treating Wilson Disease and will take over the commercialization of Galzin® within the United States. Additionally, the company has obtained the European rights to Galzin®, further expanding its reach and impact in the healthcare landscape.